AXIOS August 28, 2024
Adriel Bettelheim

Pfizer on Tuesday became the latest major drugmaker to sell medicine directly to consumers, launching a digital platform that’s initially directed at people with migraines and respiratory ailments, including COVID-19.

Why it matters: The move puts Pfizer in competition with Eli Lilly, which in January launched its own D2C platform to provide prescriptions for conditions like obesity, migraines, and diabetes.

  • The new portal could stir up more business for Pfizer drugs, though the company said patients won’t be steered to its products and that decisions will remain with physicians.

Driving the news: The PfizerForAll platform leverages partnerships with telehealth provider UpScriptHealth, online pharmacy Alto Pharmacy, and the grocery delivery service Instacart.

  • It offers $35 virtual appointments with...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Digital Health, Patient / Consumer, Pharma, Pharma / Biotech, Technology, Telehealth
Navigating Complex Regulatory Landscapes in the Biopharmaceutical Industry
How Life Sciences Can Drive Innovation And Sustainability In Returns Management
10X Genomics at JPM: New Products, New Sales Team, New Markets
Enhancing Target Screening with CRISPR Libraries: Revolutionizing Drug Discovery and Functional Genomics
Daiichi Sankyo Announces New CEO

Share This Article